TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23679192
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg (EXE)
Study: 20952373
Drug: Lipid-lowering treatment
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering treatment (e.g., statins)
Study: 20952373
Drug: Low total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low total cholesterol (<5.5 mmol/l)
Study: 20952373
Drug: Lipid-lowering treatment
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering treatment (statins)
Study: 16132121
Drug: Antioxidant-supplemented beverage
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant-supplemented beverage (30 ml.kg(‐1) pre-exercise and during exercise)
Study: 16132121
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 ml.kg(‐1) pre-exercise and during exercise)
Study: 10434218
Drug: Cisatracurium (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (0.15 or 0.2 mg/kg)
Study: 10434218
Drug: Rocuronium (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (0.9 or 1.2 mg/kg)
Study: 7843700
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) therapy for 6 months (3 to 5 million units three times a week)
Study: 7843700
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) plus Ursodeoxycholic acid (UDCA) therapy for 6 months (IFN) and 3 additional months (UDCA 10 mg/kg/d)
Study: 7843700
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) plus Ursodeoxycholic acid (UDCA) therapy
Study: 6993163
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy during pregnancy
Study: 31884472
Drug: T3D-959 (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: T3D-959 (3, 10, 30, or 90 mg daily for 14 days)
Study: 25758408
Drug: Six 1‐h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six 1‐h circuit classes targeting balance over a 2‐week period in addition to usual therapy
Study: 22588577
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral sex therapy
Study: 22588577
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral sex therapy with ginkgo biloba
Study: 22588577
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral sex therapy without ginkgo biloba
Study: 21834061
Drug: MTX in
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX in combination with TNF inhibitors
Study: 21834061
Drug: TNF inhibitors
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF inhibitors as monotherapy
Study: 21834061
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (SpA patients receiving NSAIDs/analgesics)
Study: 21834061
Drug: Concomitant prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant prednisolone treatment
Study: 19726822
Drug: Ionic high‐osmolar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ionic high‐osmolar radiographic contrast agent diatrizoate (Group A)
Study: 19726822
Drug: Non‐ionic iso‐osmolar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐ionic iso‐osmolar contrast agent iodixanol (Group B)
Study: 17461857
Drug: Alovudine 2
Normalized name: Alovudine
DrugBank: Alovudine (DB06198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alovudine 2 mg/day
Study: 17461857
Drug: Alovudine 1
Normalized name: Alovudine
DrugBank: Alovudine (DB06198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alovudine 1 mg/day
Study: 11269571
Drug: RG 12525
Normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG 12525 100 mg qd for 4 days
Study: 11269571
Drug: RG 12525
Normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG 12525 600 mg qd for 4 days
Study: 7958164
Drug: buserelin (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: buserelin (1.2 mg/day, intranasally for 3 months)
Study: 2885599
Drug: Prednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (40 mg daily for the first week, tapering off over 2 weeks)
Study: 28497396
Drug: Progressive Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive Muscle Relaxation Training (PMRT) plus Chinese Medicine Five-Element Music Therapy
Study: 21208550
Drug: AS03(A)-adjuvanted split
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03(A)-adjuvanted split H1N1 vaccine
Study: 21208550
Drug: Whole-virion (WV)
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-virion (WV) vaccine
Study: 16157857
Drug: Combination brace
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination brace and physical therapy
Study: 11955605
Drug: Cochlear implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implant children
Study: 9917226
Drug: L-754,030 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-754,030 (400 mg before cisplatin and 300 mg on days 2 to 5)
Study: 9917226
Drug: L-754,030 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-754,030 (400 mg before cisplatin and placebo on days 2 to 5)
Study: 1962596
Drug: Droloxifene 20
Normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene 20 mg once a day
Study: 1962596
Drug: Droloxifene 40
Normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene 40 mg once a day
Study: 1962596
Drug: Droloxifene 80
Normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene 80 mg once a day
Study: 1962596
Drug: Droloxifene 120
Normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene 120 mg once a day (pilot study)
Study: 7060371
Drug: 300 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 μg norethisterone (NET) minipill
Study: 7060371
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg of ethinylestradiol for 7 days
Study: 30396772
Drug: Iso-osmolar oral
Normalized name: iso-sulfan blue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iso-osmolar oral supplement (279 mOsm/kg)
Study: 30396772
Drug: Hyperosmolar oral
Normalized name: HYPEROSMOTIC LAXATIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperosmolar oral supplement (681 mOsm/kg)
Study: 28235537
Drug: Desflurane 4.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desflurane 4.1% with remifentanil 1ng/ml (R1 group)
Study: 28235537
Drug: Desflurane 3.4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desflurane 3.4% with remifentanil 3ng/ml (R3 group)
Study: 28235537
Drug: R1 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: R1 group (1ng/ml of remifentanil)
Study: 28235537
Drug: R3 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: R3 group (3ng/ml of remifentanil)
Study: 27923389
Drug: Slow infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow infusion of 5% albumin (180 minutes) at a dose of 10 ml/kg ideal body weight
Study: 27923389
Drug: Rapid infusion
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid infusion of 5% albumin (30 minutes) at a dose of 10 ml/kg ideal body weight
Study: 27923389
Drug: Both rapid
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both rapid and slow infusion of 5% albumin
Study: 22374642
Drug: Separate injection
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate injection of aspart and detemir
Study: 22374642
Drug: Mixed injection
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed injection of aspart and detemir
Study: 19319701
Drug: Prophylactic antiepileptic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antiepileptic drugs (AEDs) initiated in 23 patients (8%) without documented seizure during the first 10 days of the trial.
Study: 17000884
Drug: Enoxaparin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1.0 mg/kg every 12 hours for 5 days, followed by 1.0 mg/kg daily for 175 days
Study: 17000884
Drug: Enoxaparin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1.0 mg/kg every 12 hours for at least 5 days followed by warfarin (stable INR of 2 to 3)
Study: 12491503
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m(2)) followed by paclitaxel (175 mg/m(2) 3‐hour infusion; AT)
Study: 12491503
Drug: Doxorubicin-cyclophosphamide regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin-cyclophosphamide regimen (AC; 60/600 mg/m(2))
Study: 10664499
Drug: HBOC (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBOC (60 g for initial transfusion, with options for three more doses of 30 g each within 96 hours)
Study: 6238910
Drug: Chlorthalidone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (25 mg/day)
Study: 6238910
Drug: Severe restriction
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe restriction of salt intake (about 1016 mg Na+/day)
Study: 6238910
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified, but implied to be no treatment during initial 2 weeks)
Study: 22285545
Drug: DepoFoam bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DepoFoam bupivacaine 133 mg
Study: 22285545
Drug: DepoFoam bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DepoFoam bupivacaine 266 mg
Study: 22285545
Drug: DepoFoam bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DepoFoam bupivacaine 399 mg
Study: 22285545
Drug: DepoFoam bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DepoFoam bupivacaine 532 mg
Study: 22285545
Drug: bupivacaine HCl
Normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupivacaine HCl 150 mg
Study: 20385935
Drug: Lutein 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein 12 mg daily plus vitamin A 15,000 IU/d
Study: 20385935
Drug: Control tablet
Normalized name: Daily-Vite Weight Control Tablet
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control tablet plus vitamin A 15,000 IU/d
Study: 16214917
Drug: Low-fat, high-fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat, high-fiber diet (18 g/1,000 kcal, 3.5 servings of fruits and vegetables/1,000 kcal, 20% energy)
Study: 24471477
Drug: FSK0808 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSK0808 (200 µg/m² intravenous dose)
Study: 24471477
Drug: Gran® (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gran® (200 µg/m² intravenous dose)
Study: 24471477
Drug: FSK0808 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSK0808 (400 µg/m² subcutaneous dose)
Study: 24471477
Drug: Gran® (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gran® (400 µg/m² subcutaneous dose)
Study: 12975689
Drug: Acamprosate (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (six tablets of 333 mg/d for 12 weeks)
Study: 12975689
Drug: Placebo (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (six tablets for 12 weeks)
Study: 1394816
Drug: Adriamycin (ADM)
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin (ADM) intravesical instillation therapy
Study: 29549007
Drug: Rate Reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rate Reduction (including nicotine replacement therapy in the form of gum)
Study: 26811156
Drug: UGT1A1 genotyping
Approvals — FDA: no, EMA: no, PMDA: no
Description: UGT1A1 genotyping with irinotecan dose escalation
Study: 17478952
Drug: Continuous pump
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous pump infusion of 0.75% ropivacaine (12 mL initial dose, 6 mL/hour thereafter) in Group A
Study: 17478952
Drug: Conventional injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional injection of 0.75% ropivacaine (15 mL initial dose, 6 mL injected 80 min later) in Group B
Study: 16235667
Drug: GCF-glucose monitor;
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCF-glucose monitor; specific dosage and duration not mentioned.
Study: 12117087
Drug: 0.5% fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% fluorouracil cream (once daily)
Study: 12117087
Drug: 5% fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% fluorouracil cream (twice daily)
Study: 11374329
Drug: Treatment regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment regimen (capsule each night, as needed, or every third night)
Study: 9757979
Drug: Histamine blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine blockers (Disease-paired Control)
Study: 3144198
Drug: Nasal oxygen
Normalized name: TUBE,NASAL OXYGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal oxygen flow at 0 L/min
Study: 3144198
Drug: Nasal oxygen
Normalized name: TUBE,NASAL OXYGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal oxygen flow at 2 L/min
Study: 3144198
Drug: Nasal oxygen
Normalized name: TUBE,NASAL OXYGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal oxygen flow at 4 L/min
Study: 3144198
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine application
Study: 10922429
Drug: Simvastatin therapy
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin therapy (starting at 20 mg/day, titrated to 40 mg/day if cholesterol >5.2 mmol/L)
Study: 26003436
Drug: Telehealth behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth behavioral treatment (TBT)
Study: 20877714
Drug: Artemether-lumefantrine (AL)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (AL) treatment for fever in the intervention group
Study: 20877714
Drug: Early and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early and appropriate treatment with amoxicillin for nonsevere pneumonia in the intervention group
Study: 20877714
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treatment for fever
Study: 20877714
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treatment for nonsevere pneumonia
Study: 19927606
Drug: Ferrous glycine
Normalized name: Ferrous glycine sulfate
DrugBank: Ferrous glycine sulfate (DB14501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrous glycine phosphate and riboflavin added to school meals (28 mg of elemental iron and 1 mg of riboflavin per child per day) for 6 months.
Study: 16306925
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (10 mg daily for 6 months)
Study: 16306925
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg daily for 6 months)
Study: 16306925
Drug: Combined iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined iron and zinc supplementation (10 mg iron + 10 mg zinc daily for 6 months)
Study: 11426091
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (0.5 mg/kg) with 1% lidocaine infiltration
Study: 11426091
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (0.5 mg/kg) with normal saline infiltration
Study: 27803392
Drug: 3K3A-APC (study
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3K3A-APC (study drug), dosage not specified, used in conjunction with intra-arterial therapy (IAT)
Study: 22407197
Drug: Low-dose penicillin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose penicillin G
Study: 22407197
Drug: High-dose penicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose penicillin G
Study: 22889883
Drug: Sequential radial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential radial artery grafts (Group A)
Study: 8763594
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg 12-hourly for 8 days
Study: 8763594
Drug: Amoxicillin-clavulanate 500
Normalized name: amoxicillin-clavulanate 500 mg-125 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate 500 mg 8-hourly for 8 days
Study: 1678033
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 4000 U calcium heparin over 4 hours
Study: 1678033
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 12,500 U calcium heparin
Study: 6953729
Drug: Epidural pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural pethidine (20 or 60 mg)
Study: 6953729
Drug: Parenteral pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral pethidine (2 mg/kg body weight intramuscularly)
Study: 23374328
Drug: Micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone (400 mg/day)
Study: 10611184
Drug: 150 IU
Normalized name: Follitropin Beta 150 IU/0.5 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU daily fixed-dose regimen of recombinant follicle stimulating hormone (FSH, Puregon)
Study: 10611184
Drug: 250 IU
Normalized name: Calcium/Vitamin D 250 MG-250 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 IU daily fixed-dose regimen of recombinant follicle stimulating hormone (FSH, Puregon)
Study: 10611184
Drug: 250 IU
Normalized name: Calcium/Vitamin D 250 MG-250 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 IU daily fixed-dose regimen of recombinant follicle stimulating hormone (FSH, Puregon) in 30-33 age class
Study: 10611184
Drug: 150 IU
Normalized name: Follitropin Beta 150 IU/0.5 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU daily fixed-dose regimen of recombinant follicle stimulating hormone (FSH, Puregon) in 37-39 age class
Study: 24799585
Drug: Providing full
Approvals — FDA: no, EMA: no, PMDA: no
Description: Providing full drug coverage for nonwhite patients
Study: 24799585
Drug: Providing full
Approvals — FDA: no, EMA: no, PMDA: no
Description: Providing full drug coverage for white patients
Study: 22672221
Drug: Improved glycemic
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved glycemic control (cholesterol decreased by 17% to 4.3 ± 1.3 mmol/L)
Study: 20199979
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m2 plus carboplatin AUC 6
Study: 20199979
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m2 plus oxaliplatin 120 mg/m2
Study: 20199979
Drug: Pemetrexed treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed treatment
Study: 16081445
Drug: Daily multivitamin
Normalized name: DAILY MULTIVITAMIN TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multivitamin and multimineral supplementation
Study: 8681492
Drug: Captopril, 25
Normalized name: Captopril, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril, 25 mg three times a day for 7 days
Study: 24297763
Drug: Robotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic therapy (12 hours)
Study: 24297763
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (12 hours)
Study: 19192016
Drug: Cream containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream containing 6.0% Stryphnodendron adstringens bark extract
Study: 16002033
Drug: Daily IVR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily IVR monitoring for 28 days
Study: 16002033
Drug: Weekly IVR
Normalized name: Ivra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly IVR monitoring for 4 weeks
Study: 7917196
Drug: Prednisone therapy
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone therapy taper from 60 mg orally decreasing by 10 mg each day over 6 days
Study: 2490831
Drug: Increased treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased treatment of hypertension (antihypertensive medication)
Study: 2490831
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment of hypertension
Study: 2490831
Drug: Factors other
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factors other than antihypertensive treatment
Study: 7001039
Drug: Chloroquine prophylaxis
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine prophylaxis administered at intervals of 3 months